Unknown. May increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.


Tablets (extended release): 10 mg

Indications and dosages

To improve walking in patients with multiple sclerosis

Adults: 10 mg P.O. q 12 hours

Dosage adjustments

• Mild renal impairment


• History of seizures

• Moderate or severe renal impairment


Use cautiously in:

• mild renal impairment

• pregnant or breastfeeding patients

• children younger than age 18 (safety and efficacy not established).


• Check creatinine clearance before starting drug.

• Administer with or without food.

Adverse reactions

CNS: insomnia, dizziness, headache, asthenia, balance disorder, paresthesia, seizures

EENT: nasopharyngitis, pharyngolaryngeal pain

GI: nausea, constipation, dyspepsia

GU: urinary tract infection

Musculoskeletal: back pain

Other: multiple sclerosis relapse



Patient monitoring

Discontinue drug if seizure occurs.

• Monitor renal function tests regularly (especially creatinine clearance).

Patient teaching

• Instruct patient to take drug with or without food.

• Instruct patient to swallow tablet whole and not to break, crush, chew, or dissolve it.

Advise patient to discontinue drug and immediately report to prescriber if seizures occur.

• Instruct patient to promptly report urinary tract problems.

• As appropriate, review all other significant and life-threatening adverse reactions.


(dal-fam-pri-deen) ,


(trade name),


(trade name)


Therapeutic: anti multiple sclerosis agents
Pharmacologic: potassium channel blockers
Pregnancy Category: C


Treatment of mutiple sclerosis, to improve walking speed.


Acts as a potassium channel blocker, which may increase conduction of action potentials.

Therapeutic effects

Increased walking speed in patients with multiple sclerosis.


Absorption: Rapidly and completely absorbed (96%).
Distribution: Unknown.
Metabolism and Excretion: 96% eliminated in urine, 0.5% in feces.
Half-life: 5.2–6.5 hr.

Time/action profile (improvement in walking speed)

POunk3–4 hr24 hr


Contraindicated in: HypersensitivityHistory of seizures;Moderate/severe renal impairment (CCr ≤50 mL/min)(↑ risk of seizures); Lactation: Avoid use.
Use Cautiously in: Mild renal impairment (CCr 51–80 mL/min) (↑ risk of seizures) Geriatric: Consider age-related ↓ in renal function; Obstetric: Use only if potential benefit justifies potential risk to fetus; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness
  • headache
  • insomnia
  • weakness

Ear, Eye, Nose, Throat

  • nasopharyngitis
  • pharyngolaryngeal pain


  • constipation
  • dyspepsia
  • nausea


  • urinary tract infection


  • back pain


  • balance disorder
  • multiple sclerosis relapse
  • paresthesia


  • anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Oral (Adults) 10 mg twice daily.


Extended-release tablets: 10 mg

Nursing implications

Nursing assessment

  • Assess walking speed in patients with multiple sclerosis prior to and periodically during therapy.
  • Monitor for seizures during therapy, risk increases with increased dose. If seizure occurs, discontinue therapy.
  • Monitor for signs and symptoms of anaphylaxis (dyspnea, wheezing, urticaria, angioedema of the throat or tongue) during therapy.
  • Lab Test Considerations: Monitor creatinine clearance prior to and at least yearly during therapy; renal impairment may require dose reduction or discontinuation.

Potential Nursing Diagnoses

Impaired walking (Indications)


  • Administer tablets twice daily approximately 12 hr apart without regard to food. Administer tablets whole; do not break, crush, chew, or dissolve.

Patient/Family Teaching

  • Instruct patient to take dalfampridine as directed, with approximately 12 hrs between tablets. If a dose is missed, omit and take next scheduled dose on time; do not double doses. May increase risk of seizures. Advise patient to read Medication Guide prior to beginning therapy and with each Rx refill; new information may be available.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • If a seizure or signs or symptoms of anaphylaxis occur, advise patient to notify health care professional immediately, to discontinue dalfampridine, and to report the event to Acorda (manufacturer) at 1-800-367-5109.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Improved walking and increased walking speed in patients with multiple sclerosis.
References in periodicals archive ?
The two drugs include Dalfampridine (Ampyra) used to improve the body organs' movement in MS patients and Neurotek to treat the diabetic patients.
PHILADELPHIA -- Dalfampridine was shown to improve walking ability and balance in patients with progressive and relapsing-remitting multiple sclerosis, data presented at the annual meeting of the American Academy of Neurology show.
Dalfampridine (Ampyra) was approved in 2010 by the FDA for all types of MS; this drug enhances nerve function, and research has shown that it may improve walking speed by as much as 25 percent in some MS patients.
The Food and Drug Administration's evaluation of postmarketing adverse event reports for the multiple sclerosis drug dalfampridine indicates that the risk of seizures is highest soon after starting treatment with the recommended dose.
There are no human pregnancy data on the two new agents for the treatment of multiple sclerosis, dalfampridine (Ampyra; C) and fingolimod (Gilenya; C).
With respect to symptomatic treatment, a review of three trials of dalfampridine indicated the reported improvement in walking speed was sufficient to be clinically meaningful.
Ampyra is an extended release tablet formulation of the investigational drug dalfampridine (4-aminopyridine and called fampridine outside the U.
A sustained-release formulation of the potassium channel blocker dalfampridine has been approved as a treatment to improve walking in people with multiple sclerosis.
Solicitation: Hines cmop dalfampridine bulk order needed dalfampridine 10 mg sa tablets (900 bottle)